Sugi Predict

Sugi Predict / Compounds / Benzamide

Benzamide

Benzamide

SCHEMBL4198407

C1COCCN1.NC(=O)c1ccccc1

nearest known ligand 0.59

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.59
▸ HSD17B10 Q99714 2/20 0.59
▸ MAPT P10636 2/20 0.59
▸ POLB P06746 1/20 0.59
▸ CYP3A4 P08684 1/20 0.59
▸ PARP1 P09874 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ RECQL P46063 1/20 0.59
▸ BLM P54132 1/20 0.59
▸ PMP22 Q01453 1/20 0.59
▸ TDP1 Q9NUW8 1/20 0.59
▸ L3MBTL1 Q9Y468 1/20 0.59
▸ OPRD1 P41143 2/20 0.49
▸ SIGMAR1 Q99720 1/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ PARP10 Q53GL7 3/20 0.43
▸ PLA2G10 O15496 1/20 0.43
▸ PLA2G2A P14555 1/20 0.43
▸ LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzamide SCHEMBL28244650 0.86 MAPT (0.73) TSHRHSD17B10MAPTPOLBCYP3A4
Benzamide SCHEMBL572737 0.86 TSHR (0.73) TSHRHSD17B10MAPTPOLBCYP3A4
Benzoic Acid SCHEMBL7026585 0.85 TSHR (0.56) TSHRHSD17B10MAPTOPRD1SIGMAR1
Benzophenone SCHEMBL27861703 0.85 ALDH1A1 (0.59) TSHRHSD17B10MAPTTDP1L3MBTL1
Morpholine SCHEMBL28240748 0.83 SIGMAR1 (0.46) TSHRHSD17B10MAPTL3MBTL1SIGMAR1
Benzoic Acid SCHEMBL9285867 0.83 TSHR (0.54) TSHRHSD17B10MAPTOPRD1SIGMAR1
Benzamide SCHEMBL28688891 0.82 MAPT (0.67) TSHRHSD17B10MAPTPOLBCYP3A4
Benzamide SCHEMBL4726018 0.82 TSHR (0.67) TSHRHSD17B10MAPTPOLBCYP3A4
Acetophenone SCHEMBL9448713 0.81 OPRD1 (0.49) TSHRHSD17B10MAPTCYP2C19TDP1
Benzamide SCHEMBL694831 0.81 TSHR (0.64) TSHRHSD17B10MAPTPOLBCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111377911-B Morpholine benzamide compound and application thereof 江苏恩华药业股份有限公司 2022-05-24 — — CN disclosed
CN-111377911-B Morpholine benzamide compound and application thereof 江苏恩华药业股份有限公司 2022-05-24 — — CN disclosed
CN-111377911-B Morpholine benzamide compound and application thereof 江苏恩华药业股份有限公司 2022-05-24 — — CN disclosed
CN-111377911-A Morpholine benzamide compound and application thereof 江苏恩华药业股份有限公司 2020-07-07 — — CN disclosed
CN-111377911-A Morpholine benzamide compound and application thereof 江苏恩华药业股份有限公司 2020-07-07 — — CN disclosed
CN-111377911-A Morpholine benzamide compound and application thereof 江苏恩华药业股份有限公司 2020-07-07 — — CN disclosed
CN-110317173-A Amidopyrazole class compound as FGFR irreversible inhibitor 中国科学院上海有机化学研究所 2019-10-11 — — CN disclosed
EP-1324990-B1 MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LTD (GB) 2014-10-29 — — EP disclosed
CN-1800989-B Apparatus and process for forming a printing form having a cylindrical support DU PONT 2011-11-16 — — CN disclosed
US-7560548-B2 Morpholin-acetamide derivatives for the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2009-07-14 — — US disclosed
US-20050222147-A1 Process for the preparation of morpholine derivatives and intermediates therefore GLAXO GROUP LIMITED (GB) 2005-10-06 — — US disclosed
CN-1678594-A Morpholin-acetamide derivatives for the treatment of inflammatory diseases GLAXO GROUP LTD (GB) 2005-10-05 — — CN disclosed
US-20040058923-A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases SMITHKLINE BEECHAM CORPORATION 2004-03-25 — — US disclosed
US-20040058907-A1 Compounds useful in the treatment of inflammatory diseases GLAXO GROUP LIMITED (GB) 2004-03-25 — — US disclosed
CN-1478084-A Compounds useful in treatment of inflammatory diseases — 2004-02-25 — — CN disclosed
EP-1324991-A1 COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-07-09 — — EP disclosed
EP-1324990-A1 MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2003-07-09 — — EP disclosed
WO-2002026722-A1 MORPHOLIN-ACETAMIDE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2002-04-04 — — WO disclosed
WO-2002026723-A1 COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES GLAXO GROUP LIMITED (GB) 2002-04-04 — — WO disclosed
CN-1237962-A Pyrrolidinyl and pyrrolinyl ethylamine compounds as K agonists PFIZER (US) 1999-12-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058923-A1 Morpholin-acetamide derivatives for the treatment of inflammatory diseases CCR1, MALT1, REL TSHR 569/4885HSD17B10 1996/4885MAPT 930/4885
US-20050222147-A1 Process for the preparation of morpholine derivatives and intermediates therefore NISCH, MYO3B, CYP11B2 TSHR 3012/4885HSD17B10 1797/4885MAPT 1129/4885
US-20040058907-A1 Compounds useful in the treatment of inflammatory diseases TNF, IL1B, IL4 TSHR 3129/4885HSD17B10 1139/4885MAPT 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.